US Patent

US11154513 — Semifluorinated compounds

Method of Use · Assigned to Novaliq GmbH · Expires 2038-11-20 · 13y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects semifluorinated compounds used as medicaments for topical administration to the eye.

USPTO Abstract

The present invention is directed to certain semifluorinated compounds and to compositions comprising such compounds. The invention further provides the use of the compounds and of the compositions as medicaments for topical administration to the eye.

Drugs covered by this patent

Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1900`	—	Sandimmune

Patent Metadata

Patent number: US11154513
Jurisdiction: US
Classification: Method of Use
Expires: 2038-11-20
Drug substance claim: No
Drug product claim: Yes
Assignee: Novaliq GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.